NYXOAH overview

EQS-News: Nyxoah SA. / Key word(s): Personnel Nyxoah Appoints Scott Holstine as Chief Commercial Officer 15.07.2024 / 08:15 CET/CEST The issuer is solely responsible for the content of this announcement. Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of...

EQS-News: Nyxoah SA. / Key word(s): Financing Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank 03.07.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical...

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration...

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,904,962.41 Total number of securities carrying voting rights: 34,373,015 (all ordinary shares) Total number of...

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,902,793.43 Total number of securities carrying voting rights: 34,360,390 (all ordinary shares) Total number of...

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, Nyxoah received a transparency notification from FMR LLC following the crossing above the 3% threshold on May...

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced...